Patients with non-alcoholic fatty liver disease have unhealthy diets, sedentary behaviour and not enough physical activity. This lifestyle triggers liver disease and probably favours its progression. It also has significant deleterious effects on health and longevity and should therefore be corrected by first-line therapy at all stages of the disease.
| 91
RATZIU interventional studies with histological follow-up 8, 12 : 3-5% of body weight loss to improve steatosis, more than 5% to improve liver cell injury and inflammation, more than 7% for the resolution of steatohepatitis and 10% or more to improve fibrosis. This weight-dependent relationship is supported by the sequence of events in the natural history of NASH. However, sampling variability in liver biopsies and the natural fluctuations in the disease mean that reliable data can mostly be obtained from randomized controlled trials (RCT). Although several studies are available, the sample populations are limited. One well designed but small randomized study in 30 patients 13 has shown that the percent of weight reduction is correlated with the reduction in NAS score, a composite histological score that sums up steatosis, liver cell injury (ballooning) and hepatic inflammation. Steatosis, liver cell injury and inflammation clearly improved more often in participants who lost ≥7% of body weight. This has been confirmed in uncontrolled studies 14 as well as in an RCT with orlistat, a drug acting through weight loss without a direct hepatic effect. 15 The largest series so far to look into the relationship between weight loss and histological improvement was an open label uncontrolled study performed in 293 patients with histologically confirmed NASH who received intensive lifestyle and diet intervention (low fat hypocaloric diet and exercise). 16 Data show a strong correlation between weight loss and NASH resolution and weaker (but significant) correlations with the reversal of fibrosis.
Remarkably, a ≥5% weight loss resulted in resolution of steatohepatitis in 58% of patients; a ≥10% weight loss resulted in a resolution of NASH in 90% of patients and regression of fibrosis in 45% of patients. 16 Somewhat surprisingly, in this series even a <5% weight loss resulted in an improvement in fibrosis in a large proportion of patients, (45%) which is much higher than that in available RCTs. 17 Nevertheless, it is clear that: (i) moderate weight loss is associated with histological improvement of NASH and fibrosis; (ii) a higher rate of weight loss is necessary for the reversal of fibrosis than for improvement of other NAFLD histological lesions.
| HOWEFFECTIVEISWEIGHTLOSSASA THERAPEUTICINTERVENTION?
Two separate issues need to be considered for non-pharmacological, clinical outcomes: after a 9.6 year follow-up, the study was stopped for futility because of the inability of a 6% weight loss to reduce death from cardiovascular causes or to reduce myocardial infarction, stroke or hospitalization for coronary artery disease.
It is also questionable whether weight loss interventions induce hepatic histological improvement in patients with advanced liver disease. Data from the few RCTs in NASH published to date are not
Keypoints
• A 7%-10% weight loss should be the goal in all overweight/obese NAFLD or NASH patients. No particular diet seems to be clearly beneficial beyond weight loss.
• Weight loss improves liver histology including hepatic fibrosis if ≥10%. However, improvement of histologically advanced NASH by weight loss interventions is significantly decreased.
• Physical activity should be implemented because it improves metabolism, has protective effects on cardiovascular disease and the risk of cancer. Vigorous rather than moderate activity and resistance training should be encouraged.
• A sedentary lifestyle should be strongly discouraged.
sufficient. For instance, the Promrat article does not provide information on the histological severity of steatohepatitis and fibrosis in their participants and whether this influenced the therapeutic response.
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An interesting evaluation was performed of the above-mentioned open-label study by Vilar-Gomez et al. 25 The authors identified independent negative predictive factors of histological improvement in their intensive diet and lifestyle intervention : these were older age, type 2 diabetes and more severe NASH histological activity. 25 It is interesting that both the histological severity of NASH and the presence of cofactors that aggravate NASH liver injury (older age and type 2 diabetes) significantly reduced the chances that diet and lifestyle interventions improve hepatic histology. This suggests that patients with more severe NASH are less susceptible to improvement in their liver disease with non-pharmacological, non-surgical weight loss interventions.
| WHATTYPEOFDIETISMOST APPROPRIATEFORNAFLD/NASH PATIENTS?
The most important factor in dietary interventions seems to be calorie restriction. It is the main driver of weight loss and visceral adiposity, subcutaneous fat and liver fat reduction. 26 Relatively small amounts of weight loss result in significant reductions in liver fat and improvement in hepatic insulin resistance 27 although there are no data on other histological end-points. The macronutrient composition of the diet does not matter for the outcome as long as weight loss is achieved. 26, 28 Certain data suggest that carbohydrate-deficient diets have an early beneficial effect on hepatic fat and insulin sensitivity. 29, 30 However, this might not make a difference, in the long term when overall weight loss is obtained and insulin-resistant sites other than the liver are studied. 29 Other studies did not confirm differences between low carbohydrate and low fat diets as long as they are both calorie restricted. A recent study comparing low carbohydrate and low fat diets in a rigorous crossover design and using inpatient food-intake monitor- 40 One study performed in Greece and Italy in patients with newly diagnosed hepatocellular carcinoma has shown that close adherence to the Mediterranean diet reduces the risk of developing this neoplasm by a third. 41 The inverse relationship was roughly monotonic and individuals with the highest adherence had a 50% risk reduction. Most patients in this study had hepatitis B or C, so we lack specific data for NASH. There are numerous reports of an inverse relationship between this diet and numerous other forms of cancer.
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| UNHEALTHYDIETANDNAFLD
NAFLD patients have unhealthy diets characterized by overconsumption of fructose and soft drinks, lower consumption of fibre, overconsumption of meat, saturated fat and cholesterol, lower consumption of fish or omega-3 fatty acids or PUFA, and lower consumption of certain vitamins. [44] [45] [46] Animal data suggest that, independent of weight loss, switching from a high fat to a healthy diet lowers liver fat content, improves hepatic inflammation and arrests liver fibrosis. Cellular mechanisms include a change from the M1 to the M2, anti-inflammatory phenotype of macrophages, an inhibition of stellate cell activation and a reduction in NF-kB induction.
This attenuates the severity of NASH and fibrotic progression but weight loss is necessary for a total reversal of steatosis and hepatic apoptosis. Nonetheless these data give biological support to the beneficial effects of a healthy, physiological diet for NASH patients.
Overconsumption of meat and insufficient intake of vegetables | 93 RATZIU could also contribute to an increased risk of liver cancer 47, 48 Many studies have concentrated on the deleterious hepatic and metabolic effects of fructose which is excessively consumed in NASH patients. 46 Some data have shown that high fructose consumption, possibly industrial fructose only (not fruit fructose) 49 increases the risk of fibrosis in NASH patients. 50 In overweight/obese individuals dietary fructose specifically increases de novo lipogenesis, promotes dyslipidaemia, increases visceral adiposity and insulin resistance. 51 It is not entirely clear, however, whether the excess risk is not in fact because of excess calorie intake (whatever the type of sugar) 52 or if it is not confounded by an overall unhealthy lifestyle pattern that includes smoking, lack of exercise, diets rich in fat, poor in fibre, etc. 53 Well designed, prospective studies that take into account multiple confounders are needed to more clearly establish the epidemiological basis of this association. Nevertheless, experimental studies have shown that while HFD alone only induces steatosis, HFD + high sucrose diets induce steatohepatitis, inflammation oxidative stress and fibrosis. 54 
| LACKOFEXERCISEISAMAJOR CAUSEOFCHRONICDISEASES
It has been estimated that physical inactivity causes 6% of the burden of disease from coronary heart disease, 7% of type 2 diabetes and 10% of breast and colon cancer. 55 Nine percent of the premature deaths worldwide may be caused by the lack of physical activity. 
| PHYSICALACTIVITYAND SEDENTARITYINNAFLDPATIENTSAND ITSCONSEQUENCES
Half of NAFLD patients are inactive including almost a third that do virtually no physical exercise 56, 57 Physical inactivity has been associated with increased body weight, central adiposity, and insulin resistance as well as an increased risk of the metabolic syndrome. 58,59. It has long been recognized that physical activity is inversely related to the amount of liver fat, but this seems to be especially true for high levels of physical activity. 60 Data from animal models further support the association between exercise and fatty liver. 61, 62 In a large cross- The impact of physical exercise in NAFLD patients has been reported in a few studies. Moderately intense physical activity (60- 150 min per week) in three sessions resulted in biochemical (ALT) and in metabolic improvement (mainly glucose and HOMA) even in the absence of weight loss. 64 Uncontrolled interventional studies have confirmed that insulin resistance and ALT are reduced in patients who are compliant for exercise have a reduction in compared to non-compliant patients. 65 Two important issues must still be clarified. One of them is to understand the benefits of exercise per se, independent of dietary changes and weight loss. The other is to determine whether there are differential benefits between resistance exercise (anaerobic, muscle strengthening) and aerobic exercise.
A randomized study compared these two types of exercise and showed that both of them reduce hepatic fat content, visceral and subcutaneous fat and improved insulin sensitivity and the lipid profile comparably. Although weight was also reduced in both arms of the study there was no concomitant reduction in ALT. 66 In contrast, another controlled study 67 showed only a modest reduction in liver fat and no improvement in lipoprotein metabolism with exercise, in the absence of weight loss. A meta-analysis has shown that exercise alone significantly reduces hepatic fat content, a benefit occurring with minimal or no weight loss. 68 The effect on the other histological lesions of NASH remains unknown. Unfortunately, all of methodologies in these studies did not take into account the numerous confounders.
One study concluded that resistance exercise reduces liver fat (with the resolution of NAFLD in some cases), improves glucose control and insulin sensitivity and promotes fat oxidation, even without weight loss or impact on visceral fat. 69 However, patients that benefit most from exercise interventions are those that have a certain level of cardiorespiratory fitness at baseline, 70 which represents only a minority of NAFLD patients. 59 Another major limitation, which is a real-life problem, is that most NAFLD patients have high levels of fatigue, associated with inactivity and daytime sleepiness, 71 thus reducing compliance to physical exercise.
While engaging in physical exercise is beneficial, avoiding sedentarity is equally important. Sedentarity increases all-cause mortality independent of physical activity 72 and is predictive of higher levels of insulin resistance 73 and reducing sitting time improves insulin sensitivity. 74 No specific studies are available in NAFLD, but since this only requires minimal disruption of daily activities by short bouts of walking, it should be part of lifestyle changes in all NAFLD patients. 
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